Stockscreener 앱 받기
67.12
3.02%
-2.09
시간 외 거래:
67.10
-0.02
-0.03%
전일 마감가:
$69.21
열려 있는:
$69.21
하루 거래량:
2.14M
Relative Volume:
1.26
시가총액:
$7.96B
수익:
$1.40B
순이익/손실:
$316.89M
주가수익비율:
26.94
EPS:
2.4918
순현금흐름:
$644.59M
1주 성능:
+4.68%
1개월 성능:
-1.37%
6개월 성능:
-4.16%
1년 성능:
+37.12%
1일 변동 폭
$66.31
$69.66
1주일 범위
$63.50
$73.89
52주 변동 폭
$48.64
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
67.12 | 8.21B | 1.40B | 316.89M | 644.59M | 2.4918 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Halozyme Therapeutics Q1 2026 Earnings Review | HALO StockNews and Statistics - IndexBox
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO) - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook - Yahoo Finance
Morgan Stanley Smith Barney files Form 144 (NASDAQ: HALO) to sell 14,700 shares - Stock Titan
A Look At Halozyme Therapeutics (HALO) Valuation After Q1 Growth, GSK ENHANZE Deal And US$1b Buyback - Sahm
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up - MSN
Arbejdsmarkedets Tillaegspension Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme outlines ENHANZE royalties exceeding $1B in 2026 while launching a new $1B buyback - MSN
Halozyme appoints Darren Snellgrove as CFO - MSN
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75 - Moomoo
Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative - Sahm
HALO Stock Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of Stock - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 10,000 Shares - MarketBeat
Halozyme CEO Helen Torley sells $3.43m in stock By Investing.com - Investing.com Nigeria
Halozyme CEO Helen Torley sells $3.43m in stock - Investing.com
Halozyme (HALO) CEO Torley exercises 50K options and sells 50K shares under 10b5-1 plan - Stock Titan
(HALO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Halozyme Therapeutics Earnings: What To Look For From HALO - Yahoo Finance UK
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK - Insider Monkey
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $93 - Moomoo
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $66.41 - Moomoo
HALO Stock Jumps After Earnings Beat And $1B Buyback - StocksToTrade
Halozyme jumps as Q1 results, $1B buyback authorization, and new partnership updates lift sentiment - Quiver Quantitative
Morgan Stanley Cuts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00 - MarketBeat
Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley - marketscreener.com
Halozyme Therapeutics Shares Jumping 8.1% on Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlights: Record Revenue Growth and … - AlphaStreet
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript - Insider Monkey
Citizens reiterates Halozyme stock rating on strong Q1 results By Investing.com - Investing.com Nigeria
Morgan Stanley Cuts Price Target on Halozyme Therapeutics to $93 From $96, Keeps Overweight Rating - marketscreener.com
Citizens reiterates Halozyme stock rating on strong Q1 results - Investing.com
Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlight - GuruFocus
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $96 - Moomoo
HALO Maintained by Morgan Stanley -- Price Target Lowered to $93 - GuruFocus
Halozyme Therapeutics (HALO) Reports Strong Q1 2026 Earnings and Growth Outlook - GuruFocus
Halozyme Therapeutics Q1 Earnings Call Highlights - Inkl
Halozyme Q1 2026 slides: revenue surges 42%, $1B buyback unveiled - Investing.com Canada
Halozyme Reports Strong Q1 2026 Earnings and Strategic Outlook - Intellectia AI
Halozyme (HALO) Q1 2026 Earnings Transcript - AOL.com
Halozyme Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HALO) 2026-05-11 - Seeking Alpha
Halozyme Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook - Insider Monkey
HALO Posts Strong Q1 Results and Announces $1B Share Repurchase Program - GuruFocus
Earnings call transcript: Halozyme Q1 2026 sees strong earnings, stock rises By Investing.com - Investing.com Nigeria
Earnings call transcript: Halozyme Q1 2026 sees strong earnings, stock rises - Investing.com
MSN Money - MSN
Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Surges After Q1 Beat, Launches $1 Billion Buyback - ChartMill
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.71%
자본화:
|
볼륨(24시간):